Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Early Phase 1First-in-human
1(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Completed1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (100.0%)

Trials by Status

completed133%
recruiting133%
unknown133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingearly_phase_1

Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

NCT06190158
unknown

Cortisol Secretion, Sensitivity and Activity and Hypertension

NCT05766085
completed

Appropriate Limit Value for 1 mg DST in Patients With Chronic Renal Failure

NCT05568602

Clinical Trials (3)

Showing 3 of 3 trials
NCT06190158Early Phase 1

Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

Recruiting
NCT05766085

Cortisol Secretion, Sensitivity and Activity and Hypertension

Unknown
NCT05568602

Appropriate Limit Value for 1 mg DST in Patients With Chronic Renal Failure

Completed

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3